

## 6.a La sclerosi sistemica

Irene Miniati, Silvia Bellando Randone, Marco Matucci Cerinic

- Åkesson A., Scheja A., Lundin A., Wollheim F.A. (1994), *Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide*, in «Arthr. Rheum.», 37, pp. 729-735.
- Casale R., Buonocore M., Matucci Cerinic M. (1997), *Systemic sclerosis (scleroderma): An integrated challenge in rehabilitation*, in «Arch. Phys. Med. Rehabil.», 78(7), pp. 767-773.
- Denton C.P., Moinzadeh P. (2013<sup>4</sup>), *Systemic sclerosis*, in R.A. Watts (ed.), *Oxford textbook of rheumatology*, Oxford U.P., Oxford, pp. 969-1007.
- Kahaleh M.B. (1992), *The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy)*, in «Clin. Exp. Rheumatol.», 10, suppl. 7, pp. 51-56.
- Kahaleh M.B., Fans P.S. (1997), *Effect of cytokines on the production of endothelin by endothelial cells*, in «Clin. Exp. Rheumatol.», 15(2), pp. 163-167.
- Lapenas D., Rodman G.P., Cavallo T. (1978), *Immunopathology of the renal vascular lesion of the progressive systemic sclerosis (scleroderma)*, in «Amer. J. Pathol.», 91, pp. 243-258.
- Lee A.T., Burnet S. (2002), *Corticosteroid-induced scleroderma renal crisis*, in «Med. J. Aust.», 177(8), p. 459.
- LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A.jr et al. (1988), *Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis*, in «J. Rheumatol.», 15, pp. 202-205.
- LeRoy E.C., Medsger T.A. jr. (1992), *Raynaud's phenomenon: A proposal for classification*, in «Clin. Exp. Rheumatol.», 10, pp. 485-488.
- Matucci Cerinic M., Allano Y., Czirják L., Tyndall A., Müller-Ladner U., Denton C. et al. (2009), *The challenge of early systemic sclerosis for the EULAR Scleroderma Trial And Research group (EUSTAR) community. It is time to cut the gordian knot and develop a prevention or rescue strategy*, in «Ann. Rheum. Dis.», 68, pp. 1377-1380.
- Matucci Cerinic M., Bellando Randone S., Lepri G., Bruni C., Guiducci S. (2013), *Very early versus early disease: The evolving definition of the many faces of Systemic Sclerosis*, in «Ann. Rheum. Dis.», 72(3), pp. 319-321.
- Rodnan G.P., Whiteside T.L., Medsger T.A.jr, Rodnan G.P. (1980), *Morphologic change in the digital arteries of patient with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon*, in «Med.», 59, pp. 393-408.
- Roumm A.D., Myergowitz R.L., Justh G.O. (1984), *Lymphocytes in the skin of patients with progressive systemic sclerosis*, in «Arthr. Rheum.», 27, pp. 645-653.
- Schumacher H.R. (1973), *Joint involvement in progressive Systemic Sclerosis (scleroderma)*, in «Am. J. Clin. Pathol.», 60, pp. 593-600.
- Scorza R., Caronni M., Mascagni B., Berruti V., Bazzi S., Micallef E. et al. (2001), *Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study*, in «Clin. Exp. Rheumatol.», 19(5), pp. 503-508.
- Steen V., Medsger T.A.jr (1990), *Epidemiology and natural history of systemic sclerosis*, in «Rheum. Dis. Clin. N. Am.», 16, pp. 1-10.

- Subcommittee for Scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980), *Preliminary criteria for the classification of systemic sclerosis (scleroderma)*, in «Arthr. Rheum.», 23, pp. 581-590.
- Tyndall A., Black C., Finke J., Winkler J., Mertlesmann R., Peter H.H. et al. (1997), *Treatment of systemic sclerosis with autologous hematopoietic stem cell transplantation*, in «Lancet», 349, p. 254.
- Tyndall A., Saccardi R. (2005), *Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: Results from phase I/II studies, prospective randomized trials and future directions*, in «Clin. Exp. Immunol.», 141(1), pp. 1-9.
- Valentini G., Cuomo G., Abignano G., Petrillo A., Vettori S., Capasso A. et al. (2011), *Early systemic sclerosis: Assessment of clinical and preclinical organ involvement in patients with different disease features*, in «Rheumatology» (Oxford), 50, pp. 317-323.
- Van den Hoogen F.H., Boerbooms M., Swaak A.J., Rasker J.J., Van Lier H.J., Van de Putte L.B. (1996), *Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24-week randomized double-blind trial, followed by a 24-week observational trial*, in «Br. J. Rheumatol.», 35, pp. 364-372.
- Van den Hoogen F.H., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., Matucci Cerinic M., Naden R.P. et al. (2013), *Classification criteria for systemic sclerosis: An ACR-EULAR collaborative initiative*, in «Arthr. Rheum.», 65(11), pp. 2737-2747.
- White B., Moore W.C., Wigley F.M., Qing Xiao H., Wise R.A. (2000), *Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis*, in «Ann. Intern. Med.», 132, pp. 947-954.